Influencia de morfología, fase y tamaño de sulfuro de cobre como catalizador en la fotodegradación de contaminantes

Análisis bibliográfico de sulfuro de cobre en la fotodegradación de contaminantes. Uso de actividad frente a la velocidad de reacciónEn el presente trabajo se reporta un análisis bibliográfico del efecto de la morfología, tamaño, así como la fase de sulfuro de cobre como fotocatalizador en la degradación de contaminantes. Para dicho análisis se propone la relación % degradación / tiempo como el parámetro de actividad, la cual tiene una relación lineal con la constante de rapidez de reacción. Utilizando el parámetro de actividad calculado en las reacciones reportadas en la literatura, se estudió su relación con parámetro que presentaron los fotocatalizadores de sulfuro de cobre: relación Cu/S, dimensionalidad y tamaño. En general se encontró que la actividad incrementa a menores de relaciones de Cu/S, a mayor dimensionalidad, y disminuye cuando se incrementa el tamaño de las nanopartículas. De lo anterior se concluye que el parámetro de actividad puede ser utilizado en lugar de la constante de rapidez de reacción, así también se concluye que la actividad fotocatalítica está influida por las características del fotocatalizador.CONACYT por la beca económica con número de CVU 93618

Determination of the level of maturity in the management of projects in the Company Infotrack S.A.

Este artículo investigativo busca determinar el nivel de madurez de la gerencia de proyectos en la empresa INFOTRACK S.A. basados en el modelo Project Management Maturity Model (PMMM), el cual es el que mas se adapta las necesidades de la organización. Para lograr llevar a cabo la investigación se realizó una encuesta de 59 preguntas a los gerentes de la empresa INFOTRACK S.A. que permitiera analizar y determinar el nivel de madurez.This research paper seeks to determine the maturity level of project management in the company Infotrack S.A. based on the Project Management Maturity Model (PMMM), which is the one that best suits the needs of the organization. In order to carry out the research, a survey of 59 questions was made to the managers of the company INFOTRACK S.A. that would allow to analyze and determine the level of maturity.Especialista en Gerencia de Proyecto

Agroforestry is paying off – Economic evaluation of ecosystem services in European landscapes with and without agroforestry systems

The study assessed the economic performance of marketable ecosystem services (ES) (biomass production) and non-marketable ecosystem services and dis-services (groundwater, nutrient loss, soil loss, carbon sequestration, pollination deficit) in 11 contrasting European landscapes dominated by agroforestry land use compared to business as usual agricultural practice. The productivity and profitability of the farming activities and the associated ES were quantified using environmental modelling and economic valuation. After accounting for labour and machinery costs the financial value of the outputs of Mediterranean agroforestry systems tended to be greater than the corresponding agricultural system; but in Atlantic and Continental regions the agricultural system tended to be more profitable. However, when economic values for the associated ES were included, the relative profitability of agroforestry increased. Agroforestry landscapes: (i) were associated to reduced externalities of pollution from nutrient and soil losses, and (ii) generated additional benefits from carbon capture and storage and thus generated an overall higher economic gain. Our findings underline how a market system that includes the values of broader ES would result in land use change favouring multifunctional agroforestry. Imposing penalties for dis-services or payments for services would reflect their real world prices and would make agroforestry a more financially profitable system

Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (focus) initiative

Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. Clinical Relevance: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. Methods: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic reviewof the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE,CINAHL,SCOPUS,BIOSIS, andWeb of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review.Atotal of 44 globally representativegroupmembersmet in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. Results: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. Conclusions: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents

Expansion of Signal Transduction Pathways in Fungi by Extensive Genome Duplication

International audienceno abstrac

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

Background: Genome-wide association studies (GWAS) in Parkinson's disease have increased the scope of biological knowledge about the disease over the past decade. We aimed to use the largest aggregate of GWAS data to identify novel risk loci and gain further insight into the causes of Parkinson's disease. / Methods: We did a meta-analysis of 17 datasets from Parkinson's disease GWAS available from European ancestry samples to nominate novel loci for disease risk. These datasets incorporated all available data. We then used these data to estimate heritable risk and develop predictive models of this heritability. We also used large gene expression and methylation resources to examine possible functional consequences as well as tissue, cell type, and biological pathway enrichments for the identified risk factors. Additionally, we examined shared genetic risk between Parkinson's disease and other phenotypes of interest via genetic correlations followed by Mendelian randomisation. / Findings: Between Oct 1, 2017, and Aug 9, 2018, we analysed 7·8 million single nucleotide polymorphisms in 37 688 cases, 18 618 UK Biobank proxy-cases (ie, individuals who do not have Parkinson's disease but have a first degree relative that does), and 1·4 million controls. We identified 90 independent genome-wide significant risk signals across 78 genomic regions, including 38 novel independent risk signals in 37 loci. These 90 variants explained 16–36% of the heritable risk of Parkinson's disease depending on prevalence. Integrating methylation and expression data within a Mendelian randomisation framework identified putatively associated genes at 70 risk signals underlying GWAS loci for follow-up functional studies. Tissue-specific expression enrichment analyses suggested Parkinson's disease loci were heavily brain-enriched, with specific neuronal cell types being implicated from single cell data. We found significant genetic correlations with brain volumes (false discovery rate-adjusted p=0·0035 for intracranial volume, p=0·024 for putamen volume), smoking status (p=0·024), and educational attainment (p=0·038). Mendelian randomisation between cognitive performance and Parkinson's disease risk showed a robust association (p=8·00 × 10−7). / Interpretation: These data provide the most comprehensive survey of genetic risk within Parkinson's disease to date, to the best of our knowledge, by revealing many additional Parkinson's disease risk loci, providing a biological context for these risk factors, and showing that a considerable genetic component of this disease remains unidentified. These associations derived from European ancestry datasets will need to be followed-up with more diverse data. / Funding: The National Institute on Aging at the National Institutes of Health (USA), The Michael J Fox Foundation, and The Parkinson's Foundation (see appendix for full list of funding sources)

Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset

Mitochondrial dysfunction has been implicated in the etiology of monogenic Parkinson’s disease (PD). Yet the role that mitochondrial processes play in the most common form of the disease; sporadic PD, is yet to be fully established. Here, we comprehensively assessed the role of mitochondrial function-associated genes in sporadic PD by leveraging improvements in the scale and analysis of PD GWAS data with recent advances in our understanding of the genetics of mitochondrial disease. We calculated a mitochondrial-specific polygenic risk score (PRS) and showed that cumulative small effect variants within both our primary and secondary gene lists are significantly associated with increased PD risk. We further reported that the PRS of the secondary mitochondrial gene list was significantly associated with later age at onset. Finally, to identify possible functional genomic associations we implemented Mendelian randomization, which showed that 14 of these mitochondrial functionassociated genes showed functional consequence associated with PD risk. Further analysis suggested that the 14 identified genes are not only involved in mitophagy, but implicate new mitochondrial processes. Our data suggests that therapeutics targeting mitochondrial bioenergetics and proteostasis pathways distinct from mitophagy could be beneficial to treating the early stage of PD

Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability

Parkinson’s disease (PD), with its characteristic loss of nigrostriatal dopaminergic neurons and deposition of α-synuclein in neurons, is often considered a neuronal disorder. However, in recent years substantial evidence has emerged to implicate glial cell types, such as astrocytes and microglia. In this study, we used stratified LD score regression and expression-weighted cell-type enrichment together with several brain-related and cell-type-specific genomic annotations to connect human genomic PD findings to specific brain cell types. We found that PD heritability attributable to common variation does not enrich in global and regional brain annotations or brain-related cell-type-specific annotations. Likewise, we found no enrichment of PD susceptibility genes in brain-related cell types. In contrast, we demonstrated a significant enrichment of PD heritability in a curated lysosomal gene set highly expressed in astrocytic, microglial, and oligodendrocyte subtypes, and in LoF-intolerant genes, which were found highly expressed in almost all tested cellular subtypes. Our results suggest that PD risk loci do not lie in specific cell types or individual brain regions, but rather in global cellular processes detectable across several cell types